USFDA nod to Mylan and Biocon’s biosimilar of cancer drug Neulasta – ET HealthWorld

New Delhi: The US health regulator has approved Mylan’s cancer treating biosimilar Fulphila co-developed with Biocon, the companies said today. Fulphila is the first US Food and Drug Administration ( USFDA) approved biosimilar to Neulasta and the second biosimilar from Mylan and Biocon’s joint portfolio approved in the US, they said in a joint statement.

Categories: News Feed Tags: Tags: , ,

From drug pricing and ‘biosimilars’ to opioids and culture – a wrap and podcast from the J.P. Morgan Healthcare Conference – San Francisco Business Times

It could be weeks or a year before the deals that biotech executives and financiers started at last week’s 36th J.P. Morgan Healthcare Conference come to fruition. But here’s a quick wrap – and a BioFlash podcast – of tidbits from Bay Area companies: BAGGING OPIOIDS McKesson Corp.

Categories: News Feed Tags: Tags: